Lack of Relation of AKAP12 with p53 and Bcl-2 in Colorectal Carcinoma

  • Suren, Dinc (Pathology, Antalya Education and Research Hospital) ;
  • Yildirim, Mustafa (Medical Oncology, Ministry of Health Batman Regional Govermant Hospital) ;
  • Alikanoglu, Arsenal Sezgin (Pathology, Antalya Education and Research Hospital) ;
  • Kaya, Vildan (Radiation Oncology, Suleyman Demirel University School of Medicine) ;
  • Yildiz, Mustafa (Medical Oncology, Antalya Education and Research Hospital) ;
  • Dilli, Utku Donem (Medical Oncology, Antalya Education and Research Hospital) ;
  • Sezer, Cem (Pathology, Antalya Education and Research Hospital)
  • Published : 2014.04.30


Background: AKAP12 inhibits oncogenic proliferation, invasion, chemotaxis and neovascularization. Bcl-2 and p53 are two important apoptotic markers that play roles in apoptotic processes. It has been found that AKAP12 blocks the cell cycle and induces apoptosis in fibrosarcoma cells. In our study we assessed the relationship of AKAP12 with apoptotic markers, Bcl-2 and p53. Materials and Methods: Our study included 45 cases that were histopathologically diagnosed with colorectal carcinoma from the tissue samples acquired by surgical resection. AKAP 12, Bcl-2, and p53 expression was examined by immunohistochemistry. Results: A total of 45 colorectal adenocarcinoma patients - 17 (37.8%) females and 28 (62.2%) males - were included in this study. AKAP12 expression was found to be negative in 8 patients (17.8%), and positive in 37 patients (82.2%). Bcl-2 was found positive in 6 patients (13.3%) and p53 in 29 patients (55.6%). AKAP12 expression had no significant relation with Bcl-2 and p53 expression (p:0.939, p:0.079, respectively). Conclusions: Although various studies have pointed to apoptotic activity of AKAP12, the literature is limited regarding relations with p53 or Bcl-2 expression. In the present study, we found no relation in colorectal carcinomas.



  1. Acebedo AR, Amor EC, Jacinto SD (2014). Apoptosis-inducing activity of HPLC fraction from Voacanga globosa (Blanco) Merr. on the human colon carcinoma cell. Asian Pac J Cancer Prev, 15, 617-22.
  2. Chapline C, Cottom J, Tobin H, et al (1998). A major, transformation-sensitive PKC-binding protein is also a PKC substrate involved in cytoskeletal remodeling. J Biol Chem, 273, 19482-99.
  3. Choi MC, Jong HS, Kim TY, et al (2004). AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene, 23, 7095-103.
  4. Daoud SS, Munson PJ, Reinhold W, et al (2003). Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res, 63, 2782-93.
  5. Gelman IH (2010). Emerging Roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis. Genes Cancer, 1, 1147-56.
  6. Gelman IH (2002). The role of SSeCKS/gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front Biosci, 7, 1782-97.
  7. Gordon T, Grove B, Loftus JC, et al (1992). Molecular cloning and prelimnary haracteriztion of a novel cytoplasmic antigen recognized by myasthenia gravis sera. J Clin Invest, 90, 992-9.
  8. Jalali MM, Heidarzadeh A, Zavarei MJ, Sarmast H (2011). p53 overexpression impacts on the prognosis of laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev, 12, 1731-4.
  9. Jin Z, Hamilton JP, Yang J, et al (2008). Hypermethylation of the AKAP12 promoter is a biomarker of Barrett’s-associated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev, 17, 111-7.
  10. Kerns BJ, Jordan PA, Moore MB, et al (1992). p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem, 40, 1047-51.
  11. Kim GP, Colangelo LH, Wieand HS, et al (2007). National Cancer Institute. Prognostic and predictive roles of highdegree microsatellite instability in colon cancer: a National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol, 25, 767-72.
  12. Li HY, Zhang Y, Cai JH, Bian HL (2013). MicroRNA-451 inhibits growth of human colorectal carcinoma cells via downregulation of Pi3k/Akt pathway. Asian Pac J Cancer Prev, 14, 3631-4.
  13. Lin X, Nelson PJ, Frankfort B, et al (1995). Isolation and characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed in cells transformed by src and ras. Mol Cell Biol, 15, 2754-62.
  14. Lin X, Tombler E, Nelson PJ, Ross M, Gelman IH (1996). A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. J Biol Chem, 271, 28430-8.
  15. Lin X, Nelson P, Gelman IH (2000). SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D. Mol Cell Biol, 20, 7259-72.
  16. Liu W, Guan M, Hu T, Gu X, Lu Y (2011). Re-expression of AKAP12 inhibits progression and metastasis potential of colorectal carcinoma in vivo and in vitro. PLoS One, 6, 24015.
  17. Menezes HL, Juca MJ, Gomes EG, et al (2010). Analysis of the immunohistochemical expressions of p53, Bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors. Arq Gastroenterol, 47, 141-7.
  18. Mitra PS, Basu NK, Owens IS. (2009) Src supports UDPglucuronosyltransferase-2B7 detoxification of catechol estrogens associated with breast cancer. Biochem Biophys Res Commun, 382, 651-6.
  19. Nauert JB, Klauck TM, Langeberg LK, Scott JD (1997). Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol, 7, 52-62.
  20. Sasaki H, Kunimatsu M, Fujii Y, et al (2001). Autoantibody to gravin is expressed more strongly in younger and nonthymomatous patients with myasthenia gravis. Surgery Today, 31, 1036-7.
  21. Shih M, Lin F, Scott JD, Wang HY, Malbon CC (1999). Dynamic complexes of beta2-adrenergic receptors with protein kinases and phosphatases and the role of gravin. J Biol Chem, 274, 1588-95.
  22. Tessema M, Belinsky SA (2008). Mining the epigenome for methylated genes in lung cancer. Proc Am Thorac Soc, 5, 806-10.
  23. Vermeulen K, Berneman ZN, Van Bockstaele DR (2003). Cell cycle and apoptosis. Cell Prolif, 36, 165-75.
  24. Yildirim M, Paydas S, Tanriverdi K, et al (2007). Gravin gene expression in acute leukaemias: clinical importance and review of the literature. Leuk Lymphoma, 48, 1167-72.
  25. Yildirim M, Suren D, Goktas S, et al (2012). The predictive role of Bcl-2 expression in operable locally advanced or metastatic gastric carcinoma. J BUON, 17, 106-9.
  26. Yoon DK, Jeong CH, Jun HO, et al (2007). AKAP12 induces apoptotic cell death in human fibrosarcoma cells by regulating CDKI-cyclin D1 and caspase-3 activity. Cancer Lett, 254, 111-8.
  27. Zhao DP, Ding XW, Peng JP, Zheng YX, Zhang SZ (2005). Prognostic significance of Bcl-2 and p53 expression in colorectal carcinoma. J Zhejiang Univ Sci B, 6, 1163-9.
  28. Zhu JH, Hong DF, Song YM, et al (2013). Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells. Asian Pac J Cancer Prev, 14, 1017-21.